SLDB Solid Biosciences Inc.

3.47
-0.13  -4%
Previous Close 3.6
Open 3.52
Price To Book 1.47
Market Cap 159,576,871
Shares 45,987,571
Volume 271,575
Short Ratio
Av. Daily Volume 1,596,272
Stock charts supplied by TradingView

NewsSee all news

  1. Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001

    CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing SGT-001, a gene transfer

  2. Solid Biosciences Provides Data Update from SGT-001 Development Program

    - Demonstrated expression of SGT-001 microdystrophin and nNOS function provide evidence that SGT-001 has the potential to provide therapeutic benefit for patients with Duchenne - Previously reported event observed in

  3. Solid Biosciences Provides SGT-001 Program Update

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA) has notified the

  4. Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

    CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at

  5. Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders¹ that summarizes the evidence

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 trial placed on clinical hold - November 12, 2019. Still in place as of December 18, 2019.
SGT-001
Duchenne Muscular Dystrophy

Latest News

  1. Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001

    CAMBRIDGE, Mass., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced changes to its organizational structure to create a leaner company focused on advancing SGT-001, a gene transfer

  2. Solid Biosciences Provides Data Update from SGT-001 Development Program

    - Demonstrated expression of SGT-001 microdystrophin and nNOS function provide evidence that SGT-001 has the potential to provide therapeutic benefit for patients with Duchenne - Previously reported event observed in

  3. Solid Biosciences Provides SGT-001 Program Update

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today provided a clinical update on SGT-001 and reported that the U.S. Food and Drug Administration (FDA) has notified the

  4. Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

    CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at

  5. Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders¹ that summarizes the evidence